• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CENTENE CORPORATION REPORTS SECOND QUARTER 2024 RESULTS

    7/26/24 6:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care
    Get the next $CNC alert in real time by email

    -- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.42 --

    -- Reaffirms 2024 Adjusted Diluted EPS Guidance Floor of Greater Than $6.80 --

    • Adjusted diluted EPS of $2.42, up 15% from $2.10 in the second quarter of 2023.
    • Premium and service revenues of $36.0 billion in the second quarter of 2024.
    • Membership increase of 34% in Marketplace, compared to the second quarter of 2023.

    ST. LOUIS, July 26, 2024 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today its financial results for the second quarter ended June 30, 2024. In summary, the 2024 second quarter results were as follows:

    Total revenues (in millions)

    $             39,836



    Premium and service revenues (in millions)

    $             35,973



    Health benefits ratio

    87.6 %



    SG&A expense ratio

    8.0 %



    Adjusted SG&A expense ratio (1)

    8.0 %



    GAAP diluted EPS

    $                  2.16



    Adjusted diluted EPS (1)

    $                  2.42



    Total cash flow provided by operations (in millions)

    $                2,175



    (1)

    Represents a non-GAAP financial measure. A full reconciliation of the adjusted diluted earnings per share (EPS) and adjusted selling, general and administrative (SG&A) expenses is shown in the Non-GAAP Financial Presentation section of this release.

    "While we have work to do in Medicaid as redeterminations wind down, the overall performance of the diversified portfolio enables us to remain on track for 2024 adjusted diluted EPS guidance," said Chief Executive Officer of Centene, Sarah M. London. "At the same time, we continue to make important progress on operations and quality that positions us well to serve our members and deliver long-term profitable growth."

    Other Events

    • In July, Centene entered into a definitive agreement to sell Collaborative Health Systems, a management services organization, to Astrana Health, Inc. The transaction is expected to close by the end of 2024.

        
    • In May, Centene's Kansas subsidiary, Sunflower Health Plan, was selected to continue providing managed health care services through KanCare, the State of Kansas' Medicaid and Children's Health Insurance Program (CHIP). The new, three-year contract is expected to take effect on January 1, 2025, with the option to renew for up to two, 12-month extensions.

    Awards & Community Engagement

    • Centene received several recognitions in June, including being ranked No. 22 on the annual Fortune 500 List and No. 224 on Forbes Global 2000 list, up from No. 259 in 2023. US News and World Report also named Centene to its Best Companies to Work For (Health Services Industry). Centene's Chief Health Officer, Dr. Alice Hm Chen, was named to Modern Healthcare's list of 50 Most Influential Clinical Executives 2024.

        
    • In May, Centene was named one of the Top 50 Companies for Diversity by Fair360 (formerly DiversityInc) for the fifth consecutive year. Centene ranked No. 26 on this year's list, up 11 spots from No. 37. Centene was also recognized as a Top Disability-Friendly Company 2024 by DIVERSITYCOMM Media; included as one of the Best Employers for Diversity 2024 by Forbes and for being one of America's Greatest Workplaces for Mental Wellbeing by Newsweek.

        
    • The Centene Foundation, the philanthropy arm of Centene Corporation, announced a partnership with McCormack Baron Salazar – one of the nation's affordable housing leaders – to increase access to affordable housing. The multi-year partnership is anticipated to create thousands of housing units and drive improved outcomes for Medicaid-eligible populations through increased access to health-related services.

    Membership

    The following table sets forth membership by line of business:



    June 30,



    2024



    2023

    Traditional Medicaid (1)

    11,640,900



    14,260,400

    High Acuity Medicaid (2)

    1,499,000



    1,799,200

    Total Medicaid

    13,139,900



    16,059,600

    Commercial Marketplace

    4,401,300



    3,295,200

    Commercial Group

    426,400



    435,000

    Total Commercial

    4,827,700



    3,730,200

    Medicare (3)

    1,138,400



    1,329,000

    Medicare PDP

    6,603,600



    4,493,700

    Total at-risk membership

    25,709,600



    25,612,500

    TRICARE eligibles

    2,768,000



    2,799,300

    Total

    28,477,600



    28,411,800

    (1)

    Membership includes Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Children's Health Insurance Program (CHIP), Foster Care and Behavioral Health.

    (2)

    Membership includes Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals.

    (3)

    Membership includes Medicare Advantage and Medicare Supplement.

     

    Premium and Service Revenues

    The following table sets forth supplemental revenue information ($ in millions):





    Three Months Ended June 30,





    2024



    2023



    % Change

    Medicaid

    $         20,250



    $         21,895



    (8) %

    Commercial

    8,535



    5,734



    49 %

    Medicare (1)

    5,978



    5,665



    6 %

    Other

    1,210



    1,544



    (22) %

    Total premium and service revenues

    $         35,973



    $         34,838



    3 %

    (1)

    Medicare includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans (D-SNPs) and Medicare Prescription Drug Plan (PDP).

     

    Statement of Operations: Three Months Ended June 30, 2024

    • For the second quarter of 2024, premium and service revenues increased 3% to $36.0 billion from $34.8 billion in the comparable period of 2023. The increase was primarily driven by membership growth in the Marketplace business due to strong product positioning as well as overall market growth and outperformance in Marketplace risk adjustment for the 2023 benefit year, partially offset by recent divestitures in the Other segment and lower Medicaid membership primarily due to redeterminations.

        
    • Health benefits ratio (HBR) of 87.6% for the second quarter of 2024 represents an increase from 87.0% in the comparable period in 2023. The increase was driven by higher acuity in Medicaid as we progressed through the redetermination process and continue to work with states to match rates with acuity. The increase was also driven by Medicare Star rating impacts. The increase was partially offset by Marketplace membership growth and improved margin through strong 2024 product design and execution as well as outperformance in Marketplace risk adjustment for the 2023 benefit year.

        
    • The SG&A expense ratio was 8.0% for the second quarter of 2024, compared to 8.7% in the second quarter of 2023. The adjusted SG&A expense ratio was 8.0% for the second quarter of 2024, compared to 8.6% in the second quarter of 2023. The decreases were driven by Marketplace risk adjustment revenue, the divestiture of Circle Health Group (Circle Health), which operated at a higher SG&A expense ratio, and ongoing SG&A reduction initiatives. The decreases were partially offset by growth in the Marketplace business, which operates at a meaningfully higher SG&A expense ratio as compared to Medicaid.

        
    • The effective tax rate was 24.4% for the second quarter of 2024, compared to 25.4% in the second quarter of 2023. The effective tax rate for the second quarter of 2024 reflects tax effects of settlements with taxing authorities. For the second quarter of 2024, our effective tax rate on adjusted earnings was 24.4%, compared to 24.9% in the second quarter of 2023.

        
    • Cash flow provided by operations for the second quarter of 2024 was $2.2 billion, primarily driven by net earnings and risk adjustment accruals for the 2024 benefit year.

    Balance Sheet

    At June 30, 2024, the Company had cash, investments and restricted deposits of $38.5 billion and maintained $217 million of cash and cash equivalents in its unregulated entities. Medical claims liabilities totaled $18.2 billion. The Company's days in claims payable was 54 days, an increase of one day as compared to the first quarter of 2024, and an increase of two days as compared to the second quarter of 2023. Total debt was $17.6 billion, which included no borrowings on the $2.0 billion Revolving Credit Facility at quarter end.

    During the second quarter of 2024, the Company repurchased 10.7 million shares for $800 million. As of July 26, 2024, $4.4 billion remains available under the Company's stock repurchase program.

    Outlook

    The Company reaffirms its 2024 GAAP diluted EPS guidance floor of greater than $5.94 and its 2024 adjusted diluted EPS guidance floor of greater than $6.80. A full reconciliation of adjusted diluted EPS is shown in the Non-GAAP Financial Presentation section of this release.

    The Company is increasing its 2024 premium and service revenues guidance range by $5.0 billion to a range of $141.0 billion to $143.0 billion to reflect an additional $2.0 billion Commercial premium revenue, $2.0 billion Medicare premium revenue and $1.0 billion Medicaid premium revenue. The Company's total revenue guidance has been updated to $155.0 billion to $157.0 billion. Additionally, the 2024 HBR is expected to be at the high end of the previous guidance range, approximately 87.9%.

    Conference Call

    As previously announced, the Company will host a conference call Friday, July 26, 2024, at 8:30 a.m. ET to review the financial results for the second quarter ended June 30, 2024.

    Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 4980577 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, under the Investors section.

    A webcast replay will be available for on-demand listening shortly following the completion of the call for the next 12 months or until 11:59 p.m. ET on Friday, July 25, 2025, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. ET on Friday, August 2, 2024, by dialing 1-877-344-7529 in the U.S., 1-855-669-9658 in Canada, or +1-412-317-0088 from abroad, and entering access code 7407521.

    Non-GAAP Financial Presentation

    The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    The Company believes the presentation of non-GAAP financial measures that excludes amortization of acquired intangible assets, acquisition and divestiture related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's core performance over time.

    The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):



    Three Months Ended June 30,



    Six Months Ended June 30,



    2024



    2023



    2024



    2023

    GAAP net earnings attributable to Centene

    $               1,146



    $               1,058



    $               2,309



    $               2,188

    Amortization of acquired intangible assets

    173



    179



    346



    362

    Acquisition and divestiture related expenses

    6



    13



    67



    36

    Other adjustments (1)

    2



    (74)



    (97)



    (127)

    Income tax effects of adjustments (2)

    (44)



    (21)



    (126)



    (135)

    Adjusted net earnings

    $               1,283



    $               1,155



    $               2,499



    $               2,324

     

    (1)

    Other adjustments include the following pre-tax items:



    2024:









    (a)

    for the three months ended June 30, 2024: gain on the previously reported divestiture of Circle Health of $10 million, an additional loss on the divestiture of our Spanish and Central European businesses of $7 million, severance costs due to a restructuring of $4 million, reduction to the net gain on the sale of property due to closing costs of $3 million and net gain on the finalization of working capital adjustments for the previously reported divestiture of Magellan Specialty Health of $2 million;













    (b)

    for the six months ended June 30, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $83 million, net gain on the sale of property of $21 million, gain on the previously reported divestiture of Circle Health of $20 million, Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $14 million, severance costs due to a restructuring of $13 million, an additional loss on the divestiture of our Spanish and Central European businesses of $7 million and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $7 million.



    2023:









    (a)

    for the three months ended June 30, 2023: gain on the sale of Apixio of $91 million, gain on the previously reported divestiture of Centurion of $15 million, an additional loss on the divestiture of our Spanish and Central European businesses of $13 million and real estate impairments of $19 million;













    (b)

    for the six months ended June 30, 2023: gain on the sale of Apixio of $91 million, gain on the sale of Magellan Specialty Health of $79 million, gain on the previously reported divestiture of Centurion of $15 million, an additional loss on the divestiture of our Spanish and Central European businesses of $13 million and real estate impairments of $45 million.









    (2) 

    The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment. The six months ended June 30, 2023, includes a one-time income tax benefit of $69 million resulting from the distribution of long-term stock awards to the estate of the Company's former CEO.

     



    Three Months Ended June 30,



    Six Months Ended June 30,



    Annual Guidance

    December 31, 2024



    2024



    2023



    2024



    2023



    GAAP diluted EPS attributable to

    Centene

    $         2.16



    $         1.92



    $         4.32



    $         3.96



    greater than $5.94

    Amortization of acquired intangible assets

    0.33



    0.33



    0.65



    0.66



    ~$1.32

    Acquisition and divestiture related expenses

    0.01



    0.02



    0.13



    0.07



    ~$0.13

    Other adjustments (3)

    —



    (0.13)



    (0.18)



    (0.23)



    ~$(0.19)

    Income tax effects of adjustments (4)

    (0.08)



    (0.04)



    (0.24)



    (0.25)



    ~$(0.40)

    Adjusted diluted EPS

    $         2.42



    $         2.10



    $         4.68



    $         4.21



    greater than $6.80

     

    (3)

     Other adjustments include the following pre-tax items:



     2024:









    (a)

    for the three months ended June 30, 2024: gain on the previously reported divestiture of Circle Health of $0.02 per share ($0.02 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.01 per share ($0.01 after-tax) and severance costs due to a restructuring of $0.01 per share ($0.01 after-tax);













    (b)

    for the six months ended June 30, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $0.15 per share ($0.11 after-tax), net gain on the sale of property of $0.04 per share ($0.03 after-tax), gain on the previously reported divestiture of Circle Health of $0.04 per share ($0.12 after-tax), Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $0.03 per share ($0.02 after-tax), severance costs due to a restructuring of $0.02 per share ($0.02 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.01 per share ($0.01 after-tax) and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $0.01 per share ($0.01 after-tax);













    (c)

    for the year ended December 31, 2024, an estimated: $0.16 ($0.12 after-tax) net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments, $0.04 ($0.03 after-tax) net gain on the sale of property, $0.04 ($0.12 after-tax) gain on the previously reported divestiture of Circle Health, $0.03 ($0.02 after-tax) Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract, $0.02 ($0.01 after-tax) severance costs due to a restructuring, $0.01 ($0.01 after-tax) additional loss on the previously reported divestiture of our Spanish and Central European businesses and $0.01 ($0.01 after-tax) gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments.



    2023:









    (a)

    for the three months ended June 30, 2023: gain on the sale of Apixio of $0.16 per share ($0.11 after-tax), gain on the previously reported divestiture of Centurion of $0.02 per share ($0.01 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.02 per share ($0.01 after-tax) and real estate impairments of $0.03 per share ($0.02 after-tax);













    (b)

    for the six months ended June 30, 2023: gain on the sale of Apixio of $0.16 per share ($0.11 after-tax), gain on the sale of Magellan Specialty Health of $0.14 per share ($0.12 after-tax), gain on the previously reported divestiture of Centurion of $0.03 per share ($0.02 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.02 per share ($0.01 after-tax) and real estate impairments of $0.08 per share ($0.06 after-tax).









    (4)

    The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment. The six months ended June 30, 2023, include a one-time income tax benefit of $0.12 resulting from the distribution of long-term stock awards to the estate of the Company's former CEO.

     



    Three Months Ended June 30,



    Six Months Ended June 30,



    2024



    2023



    2024



    2023

    GAAP selling, general and administrative expenses

    $                2,894



    $                3,016



    $              6,112



    $              6,027

    Less:















    Acquisition and divestiture related expenses

    6



    13



    67



    36

    Restructuring costs

    4



    —



    13



    —

    Real estate optimization

    —



    1



    —



    7

    Adjusted selling, general and administrative expenses

    $                2,884



    $                3,002



    $              6,032



    $              5,984

     

    To provide clarity on the way management defines certain key metrics and ratios, the Company is providing a description of how the metric or ratio is calculated as follows:

    • Health Benefits Ratio (HBR) (GAAP) = Medical costs divided by premium revenues.

        
    • SG&A Expense Ratio (GAAP) = Selling, general and administrative expenses divided by premium and service revenues.

        
    • Adjusted SG&A Expense Ratio (non-GAAP) = Adjusted selling, general and administrative expenses divided by premium and service revenues.

        
    • Adjusted Effective Tax Rate (non-GAAP) = GAAP income tax expense (benefit) excluding the income tax effects of adjustments to net earnings divided by adjusted earnings (loss) before income tax expense.

        
    • Adjusted Net Earnings (non-GAAP) = Net earnings less amortization of acquired intangible assets, less acquisition and divestiture related expenses, as well as adjustments for other items, net of the income tax effect of the adjustments.

        
    • Adjusted Diluted EPS (non-GAAP) = Adjusted net earnings divided by weighted average common shares outstanding on a fully diluted basis.

        
    • Debt to Capitalization Ratio (GAAP) = Total debt, divided by total debt plus total stockholder's equity.

        
    • Average Medical Claims Expense (GAAP) = Medical costs for the period divided by number of days in such period. Average medical claims expense is most often calculated for the quarterly reporting period.

        
    • Days in Claims Payable (GAAP) = Medical claims liabilities divided by average medical claims expense. Days in claims payable is most often calculated for the quarterly reporting period.

    In addition, the following terms are defined as follows:

    • State-directed Payments: Payments directed by a state that have minimal risk but are administered as a premium adjustment. These payments are recorded as premium revenue and medical costs at close to a 100% HBR. In many instances, the Company has little visibility to the timing of these payments until they are paid by a state.

        
    • Pass-through Payments: Non-risk supplemental payments from a state that the Company is required to pass through to designated contracted providers. These payments are recorded as premium tax revenue and premium tax expense.

    About Centene Corporation

    Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities and government partners.

    Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com. 

    Forward-Looking Statements

    All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "guidance," "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables, and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound including but not limited to any impacts resulting from Medicaid redeterminations; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and provide for operational resources to maintain service level requirements; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third parties; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; increased healthcare costs; inflation and interest rates; the effect of social, economic, and political conditions and geopolitical events, including as a result of changes in U.S. presidential administrations or Congress; changes in market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations made by states with regard to past practices on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought by states, the federal government or shareholder litigants, or government investigations; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs. The guidance in this press release is only effective as of the date given, July 26, 2024, and will not be updated or affirmed unless and until we publicly announce updated or affirmed guidance.

     

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (In millions, except shares in thousands and per share data in dollars)





    June 30,

    2024



    December 31,

    2023



    (Unaudited)





    ASSETS







    Current assets:







    Cash and cash equivalents

    $                  17,605



    $                  17,193

    Premium and trade receivables

    16,587



    15,532

    Short-term investments

    2,609



    2,459

    Other current assets

    1,605



    5,572

    Total current assets

    38,406



    40,756

    Long-term investments

    16,870



    16,286

    Restricted deposits

    1,415



    1,386

    Property, software and equipment, net

    2,041



    2,019

    Goodwill

    17,558



    17,558

    Intangible assets, net

    5,755



    6,101

    Other long-term assets

    1,092



    535

    Total assets

    $                  83,137



    $                  84,641

    LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND

    STOCKHOLDERS' EQUITY







    Current liabilities:







    Medical claims liability

    $                  18,173



    $                  18,000

    Accounts payable and accrued expenses

    12,232



    16,420

    Return of premium payable

    1,615



    1,462

    Unearned revenue

    597



    715

    Current portion of long-term debt

    112



    119

    Total current liabilities

    32,729



    36,716

    Long-term debt

    17,516



    17,710

    Deferred tax liability

    665



    641

    Other long-term liabilities

    4,770



    3,618

    Total liabilities

    55,680



    58,685

    Commitments and contingencies







    Redeemable noncontrolling interests

    16



    19

    Stockholders' equity:







    Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or

    outstanding at June 30, 2024 and December 31, 2023

    —



    —

    Common stock, $0.001 par value; authorized 800,000 shares; 619,495 issued and

    526,001 outstanding at June 30, 2024, and 615,291 issued and 534,484

    outstanding at December 31, 2023

    1



    1

    Additional paid-in capital

    20,461



    20,304

    Accumulated other comprehensive (loss)

    (646)



    (652)

    Retained earnings

    14,352



    12,043

    Treasury stock, at cost (93,494 and 80,807 shares, respectively)

    (6,817)



    (5,856)

    Total Centene stockholders' equity

    27,351



    25,840

    Nonredeemable noncontrolling interest

    90



    97

    Total stockholders' equity

    27,441



    25,937

    Total liabilities, redeemable noncontrolling interests and stockholders' equity

    $                  83,137



    $                  84,641

     

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (In millions, except shares in thousands and per share data in dollars)

    (Unaudited)





    Three Months Ended

    June 30,



    Six Months Ended

    June 30,



    2024



    2023



    2024



    2023

    Revenues:















    Premium

    $     35,140



    $     33,713



    $     70,669



    $     67,538

    Service

    833



    1,125



    1,641



    2,252

    Premium and service revenues

    35,973



    34,838



    72,310



    69,790

    Premium tax

    3,863



    2,770



    7,933



    6,707

    Total revenues

    39,836



    37,608



    80,243



    76,497

    Expenses:















    Medical costs

    30,765



    29,347



    61,697



    58,781

    Cost of services

    680



    877



    1,349



    1,747

    Selling, general and administrative expenses

    2,894



    3,016



    6,112



    6,027

    Depreciation expense

    133



    146



    268



    288

    Amortization of acquired intangible assets

    173



    179



    346



    362

    Premium tax expense

    3,962



    2,854



    8,123



    6,865

    Impairment

    —



    18



    13



    38

    Total operating expenses

    38,607



    36,437



    77,908



    74,108

    Earnings from operations

    1,229



    1,171



    2,335



    2,389

    Other income (expense):















    Investment and other income

    463



    425



    1,008



    778

    Interest expense

    (176)



    (181)



    (354)



    (361)

    Earnings before income tax

    1,516



    1,415



    2,989



    2,806

    Income tax expense

    370



    360



    685



    621

    Net earnings

    1,146



    1,055



    2,304



    2,185

    Loss attributable to noncontrolling interests

    —



    3



    5



    3

    Net earnings attributable to Centene Corporation

    $       1,146



    $       1,058



    $       2,309



    $       2,188

















    Net earnings per common share attributable to Centene Corporation:









    Basic earnings per common share

    $         2.16



    $         1.93



    $         4.34



    $         3.98

    Diluted earnings per common share

    $         2.16



    $         1.92



    $         4.32



    $         3.96

















    Weighted average number of common shares outstanding:













    Basic

    529,602



    548,932



    532,385



    549,850

    Diluted

    530,755



    550,308



    534,517



    551,996

     

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In millions, unaudited)





    Six Months Ended June 30,



    2024



    2023

    Cash flows from operating activities:







    Net earnings

    $           2,304



    $           2,185

    Adjustments to reconcile net earnings to net cash provided by operating activities







    Depreciation and amortization

    614



    650

    Stock compensation expense

    132



    117

    Impairment

    13



    38

    Deferred income taxes

    40



    (160)

    (Gain) loss on divestitures, net

    (103)



    (172)

    Other adjustments, net

    (11)



    68

    Changes in assets and liabilities







    Premium and trade receivables

    (1,059)



    (319)

    Other assets

    (404)



    (325)

    Medical claims liabilities

    173



    139

    Unearned revenue

    (118)



    1,895

    Accounts payable and accrued expenses

    (1,704)



    618

    Other long-term liabilities

    1,838



    2,081

    Other operating activities, net

    4



    —

    Net cash provided by operating activities

    1,719



    6,815

    Cash flows from investing activities:







    Capital expenditures

    (337)



    (440)

    Purchases of investments

    (3,434)



    (3,199)

    Sales and maturities of investments

    2,497



    2,293

    Divestiture proceeds, net of divested cash

    959



    669

    Net cash used in investing activities

    (315)



    (677)

    Cash flows from financing activities:







    Proceeds from long-term debt

    350



    1,281

    Payments and repurchases of long-term debt

    (565)



    (1,322)

    Common stock repurchases

    (954)



    (828)

    Proceeds from common stock issuances

    25



    21

    Purchase of noncontrolling interest

    —



    (85)

    Other financing activities, net

    (4)



    —

    Net cash used in financing activities

    (1,148)



    (933)

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

    7



    (7)

    Net increase in cash, cash equivalents and restricted cash and cash equivalents

    263



    5,198

    Cash, cash equivalents and restricted cash and cash equivalents, beginning of period

    17,452



    12,330

    Cash, cash equivalents and restricted cash and cash equivalents, end of period

    $         17,715



    $         17,528

    Supplemental disclosures of cash flow information:







    Interest paid

    $              352



    $              348

    Income taxes paid

    $              610



    $              592









    The following table provides a reconciliation of cash, cash equivalents and restricted cash and cash equivalents reported within the Consolidated Balance Sheets to the totals above:



    June 30,



    2024



    2023

    Cash and cash equivalents

    $         17,605



    $         17,170

    Restricted cash and cash equivalents, included in restricted deposits

    110



    358

    Total cash, cash equivalents and restricted cash and cash equivalents

    $         17,715



    $         17,528

     

    CENTENE CORPORATION

    SUPPLEMENTAL FINANCIAL DATA







    Q2



    Q1



    Q4



    Q3



    Q2





    2024



    2024



    2023



    2023



    2023

    MEMBERSHIP



















    Traditional Medicaid (1)

    11,640,900



    11,750,000



    12,754,000



    13,470,900



    14,260,400

    High Acuity Medicaid (2)

    1,499,000



    1,547,600



    1,718,000



    1,769,600



    1,799,200

    Total Medicaid

    13,139,900



    13,297,600



    14,472,000



    15,240,500



    16,059,600

    Commercial Marketplace

    4,401,300



    4,348,800



    3,900,100



    3,681,600



    3,295,200

    Commercial Group

    426,400



    422,700



    427,500



    424,200



    435,000

    Total Commercial

    4,827,700



    4,771,500



    4,327,600



    4,105,800



    3,730,200

    Medicare (3)

    1,138,400



    1,146,800



    1,284,200



    1,310,600



    1,329,000

    Medicare PDP

    6,603,600



    6,438,900



    4,617,800



    4,539,800



    4,493,700

    Total at-risk membership

    25,709,600



    25,654,800



    24,701,600



    25,196,700



    25,612,500

    TRICARE eligibles

    2,768,000



    2,768,000



    2,773,200



    2,773,200



    2,799,300

    Total

    28,477,600



    28,422,800



    27,474,800



    27,969,900



    28,411,800

    (1)

    Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health.

    (2)

    Membership includes ABD, IDD, LTSS and MMP Duals.

    (3)

    Membership includes Medicare Advantage and Medicare Supplement.

     

    NUMBER OF EMPLOYEES

    60,000



    59,900



    67,700



    67,800



    68,300





    DAYS IN CLAIMS PAYABLE

    54



    53



    54



    53



    52























    CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)

    Regulated

    $        37,421



    $        36,528



    $        36,314



    $        35,988



    $        35,799

    Unregulated

    1,078



    1,018



    1,010



    1,020



    1,046

    Total

    $        38,499



    $        37,546



    $        37,324



    $        37,008



    $        36,845























    DEBT TO CAPITALIZATION

    39.1 %



    40.0 %



    40.7 %



    41.5 %



    41.1 %

     

    OPERATING RATIOS

    Three Months Ended June 30,



    Six Months Ended June 30,



    2024



    2023



    2024



    2023

    HBR

    87.6 %



    87.0 %



    87.3 %



    87.0 %

    SG&A expense ratio

    8.0 %



    8.7 %



    8.5 %



    8.6 %

    Adjusted SG&A expense ratio

    8.0 %



    8.6 %



    8.3 %



    8.6 %

     

    HBR BY PRODUCT

    Three Months Ended June 30,



    Six Months Ended June 30,





    2024



    2023



    2024



    2023

    Medicaid

    92.8 %



    88.9 %



    91.8 %



    89.5 %

    Commercial

    73.4 %



    81.0 %



    73.4 %



    78.7 %

    Medicare (4)

    89.2 %



    86.2 %



    90.0 %



    85.7 %

    (4)

    Medicare includes Medicare Advantage, Medicare Supplement, D-SNPs and Medicare PDP.

     

    MEDICAL CLAIMS LIABILITY 

    The changes in medical claims liability are summarized as follows (in millions):

    Balance, June 30, 2023



    $                      16,884

    Less: Reinsurance recoverables



    20

    Balance, June 30, 2023, net



    16,864

    Incurred related to:





    Current period



    123,420

    Prior periods



    (1,945)

    Total incurred



    121,475

    Paid related to:





    Current period



    107,316

    Prior periods



    13,243

    Total paid



    120,559

    Plus: Premium deficiency reserve



    335

    Balance, June 30, 2024, net



    18,115

    Plus: Reinsurance recoverables



    58

    Balance, June 30, 2024



    $                      18,173

    Centene's claims reserving process utilizes a consistent actuarial methodology to estimate Centene's ultimate liability. Any reduction in the "Incurred related to: Prior periods" amount may be offset as Centene actuarially determines the "Incurred related to: Current period." Centene believes it has consistently applied its claims reserving methodology. Additionally, approximately $354 million was recorded as a reduction to premium revenues resulting from development within "Incurred related to: Prior periods" due to minimum HBR and other return of premium programs.

    The amount of the "Incurred related to: Prior periods" above represents favorable development and includes the effects of reserving under moderately adverse conditions, new markets where we use a conservative approach in setting reserves during the initial periods of operations, receipts from other third party payors related to coordination of benefits and lower medical utilization and cost trends for dates of service June 30, 2023, and prior.

    Cision View original content:https://www.prnewswire.com/news-releases/centene-corporation-reports-second-quarter-2024-results-302207365.html

    SOURCE Centene Corporation

    Get the next $CNC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNC

    DatePrice TargetRatingAnalyst
    4/8/2025$64.00Underperform → Hold
    Jefferies
    2/6/2025Buy → Hold
    Argus
    12/17/2024$80.00 → $75.00Overweight
    Analyst
    12/13/2024$79.00 → $80.00Neutral → Buy
    UBS
    12/10/2024$68.00 → $52.00Hold → Underperform
    Jefferies
    7/24/2024$83.00 → $69.00Buy → Hold
    Jefferies
    5/30/2024$83.00Neutral
    Robert W. Baird
    3/21/2024$92.00 → $85.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CNC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

      Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

      5/7/25 2:00:00 PM ET
      $CNC
      $LFST
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • CENTENE SUBSIDIARY ARIZONA COMPLETE HEALTH JOINS SETTLEMENT AGREEMENT TO MOVE FORWARD WITH STATEWIDE LONG-TERM CARE MEDICAID CONTRACT

      ST. LOUIS, May 2, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, Arizona Complete Health, the largest Medicaid health plan in Arizona, has joined the Arizona Health Care Cost Containment System (AHCCCS) – Arizona's single state Medicaid agency – and three other health plans in reaching a settlement agreement to provide managed care for the Arizona Long Term Care System (ALTCS). The ALTCS program supports nearly 26,000 Arizonans who are elderly and/or have a physical disability (EPD) with physical and behavioral healthcare, as well as pharmacy benefits and home- and co

      5/2/25 7:05:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Oklahoma Complete Health Offers New and Upgraded Benefits for SoonerSelect Members in 2025

      OKLAHOMA CITY, May 1, 2025 /PRNewswire/ -- Oklahoma Complete Health introduces new and upgraded SoonerSelect benefits to support members. Enhancements to the value-added services aim to improve health outcomes and overall well-being of members. "Oklahoma Complete Health is excited to expand the 2025 offerings to serve our members," said Oklahoma Complete Health's President and CEO Clay Franklin. "Our plan continues to prioritize the health and well-being of Oklahomans and find ways to meet their unique needs." New and upgraded benefits include: New: Diaper ClubStarting July 1,

      5/1/25 9:06:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CNC
    SEC Filings

    See more
    • Director Greco Thomas bought $1,015,750 worth of shares (17,000 units at $59.75), increasing direct ownership by 736% to 19,309 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/19/24 5:39:30 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Dallas H James bought $99,904 worth of shares (1,693 units at $59.01) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:34:06 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Blume Jessica L. bought $14,870 worth of shares (250 units at $59.48) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:33:56 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CENTENE CORP (0001071739) (Filer)

      5/5/25 9:05:53 PM ET
      $CNC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Centene Corporation

      10-Q - CENTENE CORP (0001071739) (Filer)

      4/24/25 8:18:11 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CENTENE CORP (0001071739) (Filer)

      4/24/25 8:19:02 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Centene Corporation

      SC 13G - CENTENE CORP (0001071739) (Subject)

      11/14/24 4:06:01 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/13/24 3:02:23 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/12/24 9:55:15 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Asher Andrew Lynn covered exercise/tax liability with 10,566 shares, decreasing direct ownership by 2% to 657,642 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/28/25 6:32:31 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Corporate Controller & CAO Casso Katie covered exercise/tax liability with 2,077 shares, decreasing direct ownership by 2% to 96,335 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/21/25 5:50:08 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Chief People Officer Mcnally Tanya M covered exercise/tax liability with 964 shares, decreasing direct ownership by 2% to 59,494 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/16/25 4:43:24 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Centene upgraded by Jefferies with a new price target

      Jefferies upgraded Centene from Underperform to Hold and set a new price target of $64.00

      4/8/25 9:08:11 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by Argus

      Argus downgraded Centene from Buy to Hold

      2/6/25 7:52:15 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Analyst resumed coverage on Centene with a new price target

      Analyst resumed coverage of Centene with a rating of Overweight and set a new price target of $75.00 from $80.00 previously

      12/17/24 7:34:22 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Financials

    Live finance-specific insights

    See more
    • CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

      -- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- First quarter 2025 adjusted diluted EPS of $2.90, up 28% from $2.26 in the first quarter of 2024.17% year-over-year premium and service revenue growth.Membership increases of 29% in Marketplace and 22% in Medicare PDP, compared to the first quarter of 2024.Increased 2025 premium and service revenues guidance by $6.0 billion driven by outperformance in Marketplace enrollment and Medicare member retention.ST. LOUIS, April 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025 first quarter results were as follows: Total

      4/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION TO HOST 2025 FIRST QUARTER FINANCIAL RESULTS EARNINGS CALL

      ST. LOUIS, March 18, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 first quarter financial results at approximately 6:00 a.m. ET on Friday, April 25, 2025, and host a conference call at 8:30 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 9776439 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, under the Investors

      3/18/25 4:53:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION REPORTS 2024 RESULTS

      -- 2024 Full Year Diluted EPS of $6.31; Adjusted Diluted EPS of $7.17 -- 2024 adjusted diluted EPS of $7.17, up 7% from $6.68 in 2023.Membership increases of 12% in Marketplace and 50% in Medicare PDP, compared to the fourth quarter of 2023.Executed on capital deployment with $3.0 billion of share repurchases in 2024.Increased 2025 premium and service revenues guidance by $4.0 billion driven by Medicaid revenue and better than expected membership performance during the annual enrollment period in Medicare Advantage and PDP.ST. LOUIS, Feb. 4, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today its financial results for the fourth quarter and year ended December

      2/4/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Leadership Updates

    Live Leadership Updates

    See more
    • NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

      Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

      5/7/25 2:00:00 PM ET
      $CNC
      $LFST
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • CENTENE APPOINTS KENNETH Y. TANJI TO BOARD OF DIRECTORS

      ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g

      2/24/25 4:15:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation Names First President over Individual Coverage Health Reimbursement Arrangements (ICHRA) Business

      New leadership role reflects Centene's focus on ICHRA growth ST LOUIS, Jan. 9, 2025 /PRNewswire/ -- Centene Corporation ("Centene") (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, is pleased to announce that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan

      1/9/25 9:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care